This infographic explains IQVIA’s Decentralized Trials (DCTs), which blend remote and site-based elements for patient-centric research. Survey data show 73% of patients find hybrid visits appealing, 94% of investigators favor remote options, and 70% of sites see DCTs as more inclusive. Benefits include faster recruitment, higher retention, cost efficiencies, and reduced burden. IQVIA’s secure, interoperable DCT platform integrates study activity, mobile devices, and centralized monitoring for real-time data capture and safety signal detection. With 90+ DCTs across 30 therapy areas and 210,000 participants, IQVIA delivers proven, scalable models for accelerating timelines.

Join for free to read